Does Rallies show Form 4 insider transactions for COR?

Yes. Rallies tracks COR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is COR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COR. It does not provide personalized investment advice.

COR (Cencora, Inc.) Stock Analysis - Insider Trades

Cencora, Inc. (COR) is a publicly traded Healthcare sector company. As of May 21, 2026, COR trades at $262.65 with a market cap of $50.95B and a P/E ratio of 20.19. COR moved -0.54% today. Year to date, COR is -22.34%; over the trailing twelve months it is -9.62%. Its 52-week range spans $218.65 to $377.54. Analyst consensus is strong buy with an average price target of $358.40. Rallies surfaces COR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading COR stock inside the company?

Recent COR insider activity includes Mauch Robert P. sold 3.76K, Mauch Robert P. sold 1.33K, Mauch Robert P. sold 5.10K, Battaglia Silvana sold 1.68K, and Campbell Elizabeth S sold 3.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

COR Key Metrics

Key financial metrics for COR
Metric	Value
Price	$262.65
Market Cap	$50.95B
P/E Ratio	20.19
EPS	$13.12
Dividend Yield	0.60%
52-Week High	$377.54
52-Week Low	$218.65
Volume	1.65M
Avg Volume	0
Revenue (TTM)	$328.68B
Net Income	$2.55B
Gross Margin	3.81%

Recent COR Insider Trades

Mauch Robert P. sold 3.76K (~$1.35M) on Feb 20, 2026.
Mauch Robert P. sold 1.33K (~$479.16K) on Feb 18, 2026.
Mauch Robert P. sold 5.10K (~$1.81M) on Jan 20, 2026.
Battaglia Silvana sold 1.68K (~$578.57K) on Dec 19, 2025.
Campbell Elizabeth S sold 3.35K (~$1.15M) on Dec 19, 2025.

Latest COR News

Cencora slides as Q2 adjusted EPS and cash flow miss overshadow raised outlook — May 6, 2026
Cencora drops as Walgreens early-settles forward trades and sells COR shares — Apr 21, 2026
McKesson EPS up 19.6% Drives 144% Return, Shifts Focus to Oncology — Apr 20, 2026
Cencora drops 3% as opioid-settlement costs and profit-taking pressure shares — Apr 10, 2026
Cencora to Acquire EyeSouth Partners' Retina Business for $1.1 Billion — Mar 23, 2026

COR Analyst Consensus

11 analysts cover COR: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $358.40.

Common questions about COR

Who is trading COR stock inside the company?: Recent COR insider activity includes Mauch Robert P. sold 3.76K, Mauch Robert P. sold 1.33K, Mauch Robert P. sold 5.10K, Battaglia Silvana sold 1.68K, and Campbell Elizabeth S sold 3.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for COR?: Yes. Rallies tracks COR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is COR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COR. It does not provide personalized investment advice.